ArticleInterdisciplinary sciences, computational life sciences2026
Adaptive Graph Prompting Meets Contrastive Learning: A Multi-View Framework for Metabolite-Disease Association Prediction.
Article in Interdisciplinary sciences, computational life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolite-disease associations (MDAs) are critical for advancing precision medicine, yet existing computational methods face challenges in data sparsity, noise robustness, and feature representation. We propose GPLCL (graph prompt-enhanced contrastive learning), a novel multi-view graph learning framework integrating adaptive graph prompting and contrastive learning. GPLCL introduces enhanced graph prompt features (GPF +) with attention-based node adaptation, enabling dynamic feature recalibration. Through strategic graph augmentation and self-supervised contrastive optimization, it preserves essential topological invariants while aggregating multi-scale neighborhood patterns via HeteroGraphSAGE. In the fivefold cross-validation, GPLCL achieves AUC 0.9761 and AUPR 0.9729 on dataset 1, which is the highest improvement of 0.55 to 6.37 percentage points over the existing methods; GPLCL still maintains AUC 0.9576 and AUPR 0.9499 on the highly noisy Dataset 2, which proves its excellent performance and robustness. Case studies on type 1 diabetes, obesity, and Parkinson's disease highlighted the model's potential in discovering novel MDAs, underscoring its applicability in advancing metabolomics research and translational medicine. The code is publicly available at https://github.com/yxue9/GPLCL .
Indexed as
Identifiers
40846817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.